logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Nixes Expanded Dacogen Use : Astex Pharma

dacogen-030712.jpg

Astex Pharmaceuticals Inc. (ASTX) announced Tuesday that the FDA has declined to approve Dacogen for Injection in the additional indication of acute myeloid leukemia in elderly patients who are not considered candidates for induction therapy.

Dacogen is currently approved for the treatment of myelodysplastic syndrome, which is a disease of the blood and bone marrow, and is available in more than 30 countries worldwide including, key markets such as the United States, Brazil, China, India, Russia and Turkey.

Dacogen was licensed by Astex Pharma to MGI Pharma Inc., in August 2004, which in turn, sub-licensed the drug to Janssen-Cilag, a Johnson & Johnson company in July 2006. MGI Pharma was acquired by Eisai Corp of North America in January 2008.

The supplemental New Drug Application for Dacogen for patients with acute myeloid leukemia in adults 65 years of age or older who are not considered candidates for induction therapy, which was submitted by Eisai, was based on a phase III clinical trial (DACO-016) data.

An FDA panel, which reviewed the application, voted 10 to 3 against the new use for Dacogen last month, saying that the drug did not have a favorable benefit-risk profile in the acute myeloid leukemia setting.

In line with the panel's recommendations, the FDA has also declined to approve Dacogen for additional use on the grounds that the pre-specified analysis of the primary endpoint in the study (DACO-016) did not demonstrate statistically significant superiority of Dacogen over the control arm.

The proposal for Dacogen's approval for the treatment of elderly Acute Myeloid Leukemia is under review in the European Union, and the European Medicines Agency is expected to announce its decision later this year.

ASTX closed Tuesday's trading at $1.83, down 4.19%, on a volume of 571,232 shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Citigroup Inc. on Wednesday reported a 7 percent increase in profit for the fourth quarter from last year as lower revenues were more than offset by decreases in cost of credit as well as operating expenses. Adjusted earnings for the quarter beat analysts' expectations, while revenues missed their estimates. Goldman Sachs Group Inc. (GS) reported a profit for the fourth quarter that climbed from the previous year, while quarterly net revenues grew 12 percent. Net revenues in Fixed Income, Currency and Commodities Client Execution increased by 78 percent. Both earnings per share and revenues for the fourth-quarter topped analysts' expectations. Logan Green and John Zimmer, the co-founders of transportation network company Lyft, have come out with a vision to solve the traffic woes, including congestion-priced roads and carpooling. In a Medium post called "The End of Traffic," they said that companies like Lyft van join with the federal government to start various initiatives aimed encouraging more people to carpool.
comments powered by Disqus
Follow RTT